Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

8:05 AM ET 8-K
Product Launch Celcuity Inc. CELC

Celcuity Product Launch

Celcuity Inc. announced the commercial availability of REVTORPYK™ (gedatolisib) in the United States for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation. The therapy, which was FDA-approved in July 2026, is the first to inhibit all class I PI3K isoforms and mTOR complexes to blockade the PAM pathway. The company has also launched the REVTORPYK Support Services program to assist with patient access and financial assistance.

8:04 AM ET 8-K
M&A Deal Iron Horse Acquisition II Corp. IRHO

Iron Horse Acquisition II M&A Deal with Electra Vehicles, Inc.

Iron Horse Acquisition II Corp. (IRHO) provided a status update on its pending merger with Electra Vehicles, Inc., an AI battery intelligence company. The update highlights new customer wins for Electra, including Mooving and Omega Seiki Mobility, and progress toward the Nasdaq listing five months after signing the definitive business combination agreement.

Counterparty
Electra Vehicles, Inc.
8:02 AM ET 8-K
Leadership Change Kardigan, Inc. KARD

Kardigan Leadership Change

Kardigan, Inc. appointed Kristin Reinke, currently Vice President of Finance at Google, to its Board of Directors and as chair of the Audit Committee. Simultaneously, founding board member Doug Giordano resigned from the Board and Audit Committee. Ms. Reinke will receive an initial stock option grant valued at $650,000 as part of her appointment.

Counterparty
Kristin Reinke
8:01 AM ET 8-K
Business Update Aeon Biopharma, Inc. AEON

Aeon Biopharma Business Update

AEON Biopharma received official minutes from a Type 2b meeting with the FDA regarding the biosimilar development pathway for ABP-450, a proposed biosimilar to BOTOX. The FDA agreed in principle with a proposed two-stage pharmacodynamic study design, and the company plans to submit an IND for this study in Q4 2026 with initiation expected in Q1 2027. The feedback supports a potentially streamlined development path that may leverage existing comparative human evidence to avoid or narrow the scope of standalone comparative efficacy studies.

Counterparty
FDA
8:01 AM ET 8-K
Product Launch Crypto Co CRCW

Crypto Product Launch

The Crypto Company has launched the private beta testnet for Frame, its quantum-resistant Layer 1 blockchain. The network is designed for sub-two-second settlement and utilizes NIST-standard post-quantum digital signatures (ML-DSA-87) to ensure long-term security against quantum computing threats.

“Frame’s testnet going live is a real milestone, and I am excited about how far the team has come and what Frame is going to be. It is amazing to watch transactions flowing on-chain and see people lighting up when they experience for themselves what this platform really unlocks.”

Ron Levy, Chief Executive Officer of TCC

“We set out to build a Layer 1 that is quantum-resistant from genesis, and now we have one, designed for settlement in under two seconds. That combination lets people and agents move across chains without waiting, and without worrying about tomorrow’s threats.”

Sean Docherty, Chief Blockchain Officer of TCC
7:51 AM ET 8-K
Investor Presentation Hewlett Packard Enterprise Co HPE

Hewlett Packard Enterprise Investor Presentation

Hewlett Packard Enterprise is hosting its 2026 Networking Investor Day to outline its strategy for the AI era following the integration of Juniper Networks. The company raised its fiscal 2027 Networking segment revenue growth outlook to high teens to low-20s percent and increased its annual run-rate cost synergy target for Juniper to $800 million by the end of fiscal 2028.

Counterparty
Juniper Networks
7:45 AM ET 8-K
Investor Meeting NCL Corp Ltd. NCLH

NCL Corp Investor Meeting

NCL Corporation's parent company, Norwegian Cruise Line Holdings Ltd., announced that it expects third-quarter 2026 results to exceed previous guidance due to strong revenue performance. The company also reaffirmed its full-year 2026 guidance and provided a 2027 net interest expense forecast of $860-$880 million.

7:44 AM ET 8-K
Investor Meeting Norwegian Cruise Line Holdings Ltd. NCLH

Norwegian Cruise Line Holdings Investor Meeting

Norwegian Cruise Line Holdings Ltd. announced that it expects its third-quarter 2026 results to exceed previous guidance due to strong revenue performance. The company also reaffirmed its full-year 2026 guidance and provided a 2027 net interest expense forecast of $860-$880 million following recent subsidiary transactions.

7:34 AM ET 8-K
Leadership Change General Mills Inc GIS

General Mills Leadership Change

General Mills has appointed Dana M. McNabb as Chief Executive Officer, effective January 1, 2027, succeeding Jeffrey L. Harmening who will retire from the role and become Executive Chair. McNabb, a 27-year veteran of the company and current COO, will receive a base salary of $1.35 million and a target long-term incentive award of $2.1 million as part of her promotion.

7:32 AM ET 8-K
Financial Results Jabil Inc JBL

Jabil Financial Results

Jabil reported fourth quarter revenue of $10.6 billion and full-year fiscal 2026 revenue of $36.0 billion, representing 21% year-over-year growth. The company provided strong fiscal 2027 guidance, expecting revenue to grow 24% to $44.5 billion driven by significant demand in AI infrastructure and other diversified end markets.

Term
FY2026

“We delivered a fourth quarter that exceeded our expectations, closing an exceptional fiscal 2026 in which we grew revenue 21%, expanded core operating margin 40 basis points and generated more than $1.5 billion in adjusted free cash flow.”

Mike Dastoor, CEO

“Our fiscal 2027 outlook reflects the strength of Jabil’s diversified portfolio, with accelerating AI demand complemented by solid growth in automotive, healthcare, energy infrastructure, defense and aerospace, and warehouse and retail automation.”

Mike Dastoor, CEO
7:32 AM ET 8-K
Financial Results Conagra Brands Inc. CAG

Conagra Brands Financial Results

Conagra Brands reported Q1 fiscal 2027 net sales of $2.6 billion, a 1.4% decrease, while adjusted EPS rose 5.1% to $0.41. The company reaffirmed its full-year fiscal 2027 guidance despite a challenging operating environment and a 2.1% decrease in organic volume.

Term
Q1 2027
Earnings call
Sep 30, 2026, 9:30 AM ET

“We delivered a solid start to fiscal 2027 with top line results largely in line with expectations and profit ahead of expectations amid a challenging operating environment. Importantly, we are acting on our previously outlined priorities including restoring margins, increasing investment, reducing complexity, and rebalancing capital allocation, which are translating into measurable progress across the business. While there is more work to be done, we remain on track to deliver the year and are reaffirming our fiscal 2027 guidance.”

John Brase, president and chief executive officer of Conagra Brands
7:32 AM ET 8-K
M&A Deal Aperture AC APUR

Aperture AC M&A Deal with Valley Oasis Development LLC

Aperture AC's merger target, Atlantic HPC Group Inc, completed the acquisition of 100% of Valley Oasis Development LLC, a Tennessee-based entity holding 29 MW of contracted power capacity. The acquisition increases Atlantic's total utility-approved capacity to 127 MW across four states as it prepares for its business combination with Aperture. The site is zoned for heavy industrial use, making it suitable for bitcoin mining and AI compute deployments.

Counterparty
Valley Oasis Development LLC
7:24 AM ET 8-K
Clinical Trial Data Rafael Holdings, Inc. RFL

Rafael Holdings Clinical Trial Data

Rafael Holdings announced topline results from its pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo in 94 patients with Niemann-Pick Disease Type C. While the study did not achieve statistical significance on the primary endpoint in the overall population, a prespecified analysis of patients on background therapy (83% of the study) showed a statistically significant slowing of disease progression. The company remains on track to submit a New Drug Application (NDA) to the FDA in the fourth quarter of 2026.

Counterparty
Cyclo Therapeutics, LLC
Term
96 weeks
Earnings call
Sep 30, 2026, 8:30 AM ET
7:21 AM ET 8-K
Stock Buyback Winchester Bancorp, Inc. WSBK

Winchester Bancorp Stock Buyback Update

The Board of Directors of Winchester Bancorp, Inc. has authorized a new share repurchase program to buy back up to 464,769 shares of its common stock, representing approximately 5% of its outstanding shares. The program is scheduled to commence on September 30, 2026, and will expire on September 1, 2027.

Term
through Sep 2027
7:18 AM ET 8-K
Nasdaq/NYSE Compliance Notice Professional Diversity Network, Inc. IPDN

Professional Diversity Network Nasdaq/NYSE Compliance Notice

Professional Diversity Network, Inc. has regained compliance with Nasdaq's $1.00 minimum bid price requirement for continued listing. The company's common stock maintained a closing bid price at or above $1.00 for 10 consecutive business days following a previously announced reverse stock split. Nasdaq has officially closed the matter, resolving the deficiency notice originally issued on June 5, 2026.

Counterparty
The Nasdaq Stock Market LLC
7:15 AM ET 8-K
Executive Compensation Moderna, Inc. MRNA

Moderna Executive Compensation

Moderna appointed Juan Andres as its new Chief Operating Officer, effective October 5, 2026, while announcing the retirement of Jerh Collins, Ph.D. Mr. Andres will receive an annual base salary of $800,000, a target bonus of 90%, and a new hire equity award valued at $5 million. The leadership change comes as the company expands its oncology portfolio and scales its global manufacturing network.

Counterparty
Juan Andres
7:14 AM ET 8-K
Clinical Trial Data Jade Biosciences, Inc. JBIO

Jade Biosciences Clinical Trial Data

Jade Biosciences announced preclinical data for JADE301, an anti-interferon beta monoclonal antibody being developed for dermatomyositis. The data demonstrated high-affinity binding, potent inhibition of downstream signaling, and a differentiated pharmacokinetic profile supporting infrequent subcutaneous dosing. The company expects to initiate a Phase 1 clinical trial in healthy volunteers in Q4 2026, with interim data anticipated in the second half of 2027.

7:13 AM ET 8-K
Investor Presentation Cigna Group CI

Cigna Group Investor Presentation

The Cigna Group is hosting its 2026 Investor Day to introduce its 'Lead to One' vision, focusing on personalization at scale and leadership in complex care. During the event, the company reaffirmed its full-year 2026 outlook and established a long-term average annual adjusted EPS growth target of 10-14% through 2030.

7:07 AM ET 8-K
Leadership Change Johnson Controls International plc JCI

Johnson Controls International Leadership Change

Julie Brandt, Vice President and President of Global Commercial and Field Operations, will leave Johnson Controls as part of a planned transition related to changes in the company's operating model. She will move to an advisory role on October 1, 2026, and is expected to depart the company entirely by December 31, 2026.

7:06 AM ET 8-K
M&A Deal Onar Holding Corp ONAR

Onar Holding Signs $27.8M M&A Deal with Advertise Purple LLC

ONAR Holding Corporation completed the acquisition of Advertise Purple LLC, a leading affiliate marketing agency, for total consideration of up to $27.825 million. The deal includes $12.825 million in cash, a $7.0 million promissory note, and up to $8.0 million in potential earnout payments based on gross profit thresholds through 2029. The acquisition is described as the largest in ONAR's history, significantly increasing its pro forma revenue and adding the Bloom data and analytics platform to its technology division.

Value
$27.8M
Counterparty
Advertise Purple LLC
7:05 AM ET 8-K
Clinical Trial Data Connect Biopharma Holdings Ltd CNTB

Connect Biopharma Holdings Clinical Trial Data

Connect Biopharma announced positive topline results from its global Phase 2 study of rademikibart as an add-on treatment for acute exacerbations in adults with COPD and type 2 inflammation. The study met its primary endpoint, with rademikibart reducing the rate of treatment failure by 81% and eliminating hospital readmissions or emergency department visits for new exacerbations through Week 4. The company plans to engage with the FDA to align on a Phase 3 registrational development program.

Earnings call
Sep 30, 2026, 8:00 AM ET
7:05 AM ET 8-K
M&A Deal Peoples Bancorp Inc PEBO

Peoples Bancorp Signs $728M M&A Deal with Capital Bancorp, Inc.

Peoples Bancorp Inc. (PEBO) has entered into a definitive agreement to acquire Capital Bancorp, Inc. (CBNK) in an all-stock transaction valued at approximately $728.1 million. Capital shareholders will receive 1.11 shares of Peoples common stock for each share held, creating a combined financial services franchise with approximately $14 billion in total assets. The merger expands Peoples' presence into the Washington, D.C. and Baltimore markets and adds nationwide specialty business segments including digital consumer credit and government-guaranteed lending.

Value
$728M
Counterparty
Capital Bancorp, Inc.
Earnings call
Sep 30, 2026, 10:00 AM ET

“We were looking for a transaction and a partner that strengthens our franchise well beyond scale alone, and Capital does exactly that. Its commercial banking franchise deepens our presence in the attractive Washington, D.C. and Baltimore markets, while OpenSky, Windsor Advantage and Capital Bank Home Loans add complementary nationwide businesses that further diversify our revenue and expand our growth opportunities.”

Tyler Wilcox, President and Chief Executive Officer of Peoples

“Peoples is an excellent strategic partner for Capital because it understands and values our unique business model and entrepreneurial culture.”

Edward F. "Ed" Barry, Chief Executive Officer of Capital
7:05 AM ET 8-K
M&A Deal Capital Bancorp Inc CBNK

Capital Bancorp Signs $728M M&A Deal with Peoples Bancorp Inc.

Capital Bancorp, Inc. (CBNK) has entered into a definitive agreement to be acquired by Peoples Bancorp Inc. (PEBO) in an all-stock transaction valued at approximately $728.1 million. Capital shareholders will receive 1.11 shares of Peoples common stock for each share of Capital common stock held. The merger will create a combined financial services franchise with approximately $14 billion in total assets and expand Peoples' presence into the Washington, D.C. and Baltimore markets.

Value
$728M
Counterparty
Peoples Bancorp Inc.
Earnings call
Sep 30, 2026, 10:00 AM ET
7:01 AM ET 8-K
Leadership Change American Electric Power Co Inc AEP

American Electric Power Co Leadership Change

Alicia Knapp, President of Nuclear Development at American Electric Power, has left the company effective September 29, 2026. Her departure was described as an involuntary separation, which triggers benefits under the company's Executive Severance Plan including one times her salary and target annual incentive compensation plus prorated equity vesting.

Counterparty
Alicia Knapp
7:01 AM ET 8-K
Financial Results Factset Research Systems Inc FDS

Factset Research Systems Financial Results

FactSet reported fourth quarter fiscal 2026 GAAP revenues of $634.7 million, a 6.3% increase year-over-year, driven by strong commercial execution and AI momentum. Organic ASV grew 7.0% to $2,568.2 million, though GAAP operating margin decreased to 24.7% due to higher employee compensation and restructuring charges.

Term
Q4 2026
Earnings call
Sep 30, 2026, 9:00 AM ET

“FactSet delivered strong results, highlighted by a record increase in organic ASV for both the fourth quarter and fiscal year with continued momentum across our AI and data solutions. During the year, we accelerated innovation, strengthened commercial execution, and improved productivity across the organization.”

Sanoke Viswanathan, CEO
7:01 AM ET 8-K
Leadership Change Hartford Insurance Group, Inc. HIG

Hartford Insurance Group Leadership Change

The Hartford announced that Christopher J. Swift will resign as CEO effective March 1, 2027, transitioning to the role of Executive Chair before retiring in late 2027. A. Morris Tooker, the company's current President, has been appointed to succeed Swift as CEO and will join the Board of Directors effective October 1, 2026. The Board approved a target total annual compensation opportunity for Mr. Tooker of $12 million effective upon his appointment as CEO.

6:46 AM ET 8-K
M&A Deal Hormel Foods Corp HRL

Hormel Foods Signs $1.05B M&A Deal with Brakebush Brothers, LLC

Hormel Foods has entered into a definitive agreement to acquire Brakebush Brothers, LLC, a leading value-added chicken company, for $1.055 billion in cash. The acquisition is intended to strengthen Hormel's position in the growing chicken protein category and expand its foodservice segment capabilities. The transaction is expected to close in the first quarter of Hormel's fiscal 2027.

Value
$1.05B
Counterparty
Brakebush Brothers, LLC
6:39 AM ET 8-K/A
Capital Raise Zedge, Inc. ZDGE

Zedge Capital Raise of $7.67M

Zedge, Inc. completed a private placement of 2,616,447 shares of Class B common stock and warrants to purchase 2,354,803 shares, raising $7.675 million in gross proceeds. The investment was led by Vice Chairman Howard Jonas through Chartwell Holding LLC, with participation from board member Elliot Gibber. The company intends to use the capital to accelerate the growth of its B2B AI data business, DataSeeds.AI.

Value
$7.67M
Counterparty
Chartwell Holding LLC
6:31 AM ET 8-K
Loan & Debt Hyperscale Data, Inc. GPUS

Hyperscale Data $21M Debt Financing with JGB Capital, LP

Hyperscale Data and its subsidiaries entered into an amendment to their existing loan agreement, facilitating an additional $21 million loan to affiliate Ault & Company. The amendment also extends the maturity date of all loans under the agreement to December 14, 2027, with the new debt secured by various company assets and mortgages.

Value
$21M
Counterparty
JGB Capital, LP
Term
through Dec 14, 2027
6:30 AM ET Form 4
Insider Buying ASP Isotopes Inc. ASPI

ASP Isotopes Director Robert John Andrew Ryan Buys $21.6K of Stock

Robert John Andrew Ryan, Director, bought 8,000 shares of ASP Isotopes Inc. at $2.70 a share, worth $21.6K in total on Sep 28, 2026. Shares held after the trade: 660,222 (+1.2%).

Value
$21.6K
Shares
8,000
Price
$2.70
Role
Director
Holding change
+1.2%
Trade date
Sep 28, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.